Company news from the 10/03/06 News Brief

TAP Pharmaceutical Products has agreed to a co-promotion agreement with Novartis Pharmaceuticals Corporation for Famvir (famciclovir), an oral antiviral prescription medication. Under the terms of the agreement, TAP will be responsible for promoting Famvir to the obstetrician/gynecology (OB/GYN) medical community. Financial terms of the agreement were not disclosed.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.